Haemonetics Corporation announced the election of Ellen M. Zane to its Board of Directors. Zane is a nationally renowned health care leader with more than 30 years of experience in hospitals and healthcare systems.
Zane led the turnaround of Tufts Medical Center and Floating Hospital for Children in Boston, where she retired as President and Chief Executive Officer in 2011 and currently serves as Vice Chair of the Board of Trustees. She returned the organization to financial stability and strengthened its academic relationships and community physician networks to deliver high-quality, cost-efficient and patient-centered care amid rapid change in the healthcare industry.
From 1994 to 2004, Zane was Network President of Partners HealthCare System, Inc., where she developed one of the largest physician networks in the country. Prior to this, she was Chief Executive Officer of Quincy Hospital.
Zane serves on the board of global medical technology leader Boston Scientific Corporation, as well as the boards of Brooks Automation and Fiduciary Trust Company. She is also a former director of PAREXEL International Corporation. Zane previously served on Haemonetics’ Board of Directors from 2012-2016.
“We are pleased to welcome Ellen back to our Board. Her broad expertise in health systems and physician enterprises will bring valuable insights across the company’s growth businesses, especially our Hospital business unit,” said Richard J. Meelia, Chairman of Haemonetics’ Board of Directors. “The Board is committed to renewal in support of Haemonetics’ turnaround. Ellen is the fourth director to join in the past 18 months and will add to the Board’s strong mix of operational and strategic experience as the company transforms to pursue accelerated growth.”
Zane earned a Bachelor of Arts degree from George Washington University and a Master of Arts degree from The Catholic University of America, and holds honorary doctorate degrees from Bentley University, Stonehill College and Curry College. She is on the faculty at Tufts University School of Medicine and The Harvard T. H. Chan School of Public Health.
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).